In the last trading session, 20.04 million UroGen Pharma Ltd (NASDAQ:URGN) shares changed hands as the company’s beta touched 0.39. With the company’s per share price at $7.37 changed hands at $2.23 or 43.39% during last session, the market valuation stood at $339.81M. URGN’s last price was a discount, traded about -180.87% off its 52-week high of $20.70. The share price had its 52-week low at $3.42, which suggests the last value was 53.6% up since then.
Analysts gave the UroGen Pharma Ltd (URGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended URGN as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. UroGen Pharma Ltd’s EPS for the current quarter is expected to be -0.81.
UroGen Pharma Ltd (NASDAQ:URGN) trade information
Instantly URGN was in green as seen at the end of in last trading. With action 73.82%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -30.80%, with the 5-day performance at 73.82% in the green. However, in the 30-day time frame, UroGen Pharma Ltd (NASDAQ:URGN) is -27.17% down.
The consensus price target for the stock as assigned by Wall Street analysts is 40, meaning bulls need an upside of 81.58% from its current market value. According to analyst projections, URGN’s forecast low is 22 with 60 as the target high. To hit the forecast high, the stock’s price needs a -714.11% plunge from its current level, while the stock would need to soar -198.51% for it to hit the projected low.
UroGen Pharma Ltd (URGN) estimates and forecasts
Year-over-year growth is forecast to reach 24.05% up from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of 22.89M. 8 analysts are of the opinion that UroGen Pharma Ltd’s revenue for the current quarter will be 29.32M. The company’s revenue for the corresponding quarters a year ago was 21.85M and 25.2M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 4.79%. The estimates for the next quarter sales put growth at 16.31%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.39%. The 2025 estimates are for UroGen Pharma Ltd earnings to decrease by -0.08%.
URGN Dividends
UroGen Pharma Ltd is expected to release its next quarterly earnings report in July.
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 8.9621% or 3.3 million shares worth $55.37 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were iShares Trust-iShares Russell 2000 ETF and Fidelity Salem Street Trust-Fidelity Small Cap Index Fund . With 931.26 shares estimated at $6.86 million under it, the former controlled 2.02% of total outstanding shares. On the other hand, Fidelity Salem Street Trust-Fidelity Small Cap Index Fund held about 0.83% of the shares, roughly 382.87 shares worth around $2.82 million.
